

4 March 2026

THIS ANNOUNCEMENT IS NOT FOR DISTRIBUTION IN OR INTO AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH ITS DISTRIBUTION MAY BE UNLAWFUL

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED

Bellevue Healthcare Trust plc (the "Company")

Results of General Meeting

Change of Manager, Change of Name

Results of General Meeting

The Company announces that each of the Resolutions proposed at the general meeting of the Company held at 4.30 p.m. (London time) today (the "**General Meeting**") was duly passed.

Accordingly, the appointment of Columbia Threadneedle Investment Business Limited (together with its affiliates "**Columbia Threadneedle**") as the Company's AIFM and investment manager will become effective from 5 March 2026. The Company's name will be changed to "CT Healthcare Trust plc", with the ticker symbol CTHT as soon as possible. A further announcement will be made when the change of name and ticker symbol are effective.

Resolutions were also passed to amend the Company's articles of association to remove the detailed provisions implementing the Redemption Facility previously operated by the Company and to approve the allotment and issue (or sale from treasury) for cash on a non-preemptive basis a number of Shares equal to 100 per cent. of the Shares in issue as at the date of this announcement (excluding Shares held in treasury), enabling the Company to grow in size and scale.

The Resolutions also included approval of the repurchase of up to 100 per cent. of the Company's ordinary redeemable shares of £0.01 each (the "**Shares**") in issue (excluding any Shares held in treasury) pursuant to the tender offer commenced on 12 February 2026 (the "**Tender Offer**"), further details of which are set out below.

Kate Bolsover, Chairman of the Company said:

"We are grateful for the significant support that shareholders have shown these proposals. We believe that the appointment of Columbia Threadneedle provides a highly differentiated and compelling opportunity to deliver long term risk adjusted shareholder returns from the healthcare and biotech sector."

Marrack Tonkin, Head of Investment Trusts at Columbia Threadneedle said:

"We are delighted to have secured the trust of shareholders to manage the Company on their behalf. We are excited to bring this proven strategy to a new market of investors and are keen to get started in building an investment portfolio designed to capture the upside of healthcare innovation and trends."

The results of the resolutions proposed at the General Meeting, each of which was held by poll, were as follows:

Ordinary Resolution	In favour*	% shares voted in favour	% shares in issue voted in favour	Against	% shares voted against	Votes withheld**
To change the	17,006,678	99.73	23.23	46,657	0.27	158,213

Company's investment objective and investment policy						
To approve the allotment of Shares	15,967,678	93.74	21.81	1,066,447	6.26	177,423
To approve the sale of On-Sale Shares at a price less than prevailing NAV per Share	17,804,864	98.54	24.32	264,350	1.46	164,582
Special Resolutions	In favour*	% shares voted in favour	% shares in issue voted in favour	Against	% shares voted against	Votes withheld**
To amend the Company's Articles of Association	18,012,535	99.71	24.61	52,524	0.29	168,737
To approve the issue of further Shares without pre-emption rights applying	16,661,023	92.21	22.76	1,407,906	7.79	164,867
To approve the repurchase of Shares pursuant to the Tender Offer	17,021,179	94.20	23.25	1,047,902	5.8	164,715
To approve on-market purchases by the Company of up to 14.99% of the Shares in issue pursuant to the Tender Offer	17,919,371	99.16	24.48	151,381	0.84	163,044

* Votes for include discretionary votes

** A vote withheld is a not a vote in law and is not counted in the votes for or against a resolution

The full text of the resolutions can be found in the notice of the General Meeting contained in the Company's circular to shareholders dated 12 February 2026 (the "**Circular**"), which is available for inspection at the National Storage Mechanism <https://data.fca.org.uk/#/nsm/nationalstoragemechanism> and also on the Company's website at www.bellevuehealthcaretrust.com/

Tender Offer

Further to the Tender Offer for up to 100 per cent. of the Shares in issue (excluding Shares held in treasury), launched by the Company on 12 February 2026 in connection with the Proposals, the Company also announces that 29,922,562 Shares were validly tendered pursuant to the Tender Offer, equal to

approximately 40.9 per cent. of the 73,199,234 Shares in issue.

Eligible Shareholders who validly tendered Shares in the Tender Offer shall have all tendered Shares purchased in full under the Tender Offer in accordance with the process described in the Circular.

The price at which all tendered Shares will be acquired by the Company under the Tender Offer is 139.7186 pence per Share (the "**Tender Price**").

The Tender Price has been determined by reference to the Company's NAV per Share at close of business on the Calculation Date of 3 March 2026.

It is intended that the purchase of Shares under the Tender Offer will occur on or around 6 March 2026.

As described in the Circular, Threadneedle Asset Management Holdings Limited, or another UK subsidiary or affiliate of Ameriprise Financial Inc., intends to subscribe for up to the Sterling equivalent of 25 million of new Shares in the Company to support an appropriate level of scale and liquidity in the short to medium term following completion of the Tender Offer. A further announcement will be made in due course.

Capitalised terms not otherwise defined in this announcement shall have the meanings given to them in the Circular.

For further information, please contact:

**Bellevue Healthcare
Trust plc**

Kate Bolsover, Chairman

c/o Burson Buchanan

Burson Buchanan

+44 (0) 7788 528143

Henry Wilson / Helen
Tarbet / Nick Croysdill /
Jesse McNab

BBH@buchanan.uk.com

JP Morgan Cazenove

+44 (0) 20 3493 8000

William Simmonds / Rupert
Budge

BBH_JPMC@jpmorgan.com

NSM Funds (UK) Ltd

+44 (0) 20 3697 5770

Brian Smith / Ciara
McKillop

belleuve@nsm.group

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

ROMFLFFDVTISIIR